Global Anti-TIGIT Antibody Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Anti-TIGIT Antibody Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity.
Anti-TIGIT Antibody report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Anti-TIGIT Antibody market is projected to reach US$ 787.1 million in 2029, increasing from US$ 324.8 million in 2022, with the CAGR of 13.5% during the period of 2024 to 2029. Demand from Cell Carcinoma and Solid Tumor are the major drivers for the industry.
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a protein receptor found on various immune cells, including T cells and natural killer (NK) cells. It plays a role in regulating immune responses, and targeting TIGIT has emerged as a potential therapeutic strategy for cancer and autoimmune diseases.
Clinical trials were underway to evaluate the safety and efficacy of anti-TIGIT antibodies either as monotherapy or in combination with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies). Promising results were reported from early-stage trials, showing potential benefits in various solid tumors, including lung cancer, melanoma, and gastrointestinal cancers.
The market for anti-TIGIT antibodies was expected to grow as more clinical data became available.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-TIGIT Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Roche
Merck
AstraZeneca
Arcus
Astellas
BeiGene
BMS
Junshi Biosciences
Innovent Biologics
Mereo BioPharma
Seattle Genetics
Hengrui Medicine
Compugen
Gilead Sciences
Segment by Type
Monotherapy
Combination Therapy
Cell Carcinoma
Solid Tumor
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Anti-TIGIT Antibody market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Anti-TIGIT Antibody introduction, etc. Anti-TIGIT Antibody Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Anti-TIGIT Antibody market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Anti-TIGIT Antibody report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Anti-TIGIT Antibody market is projected to reach US$ 787.1 million in 2029, increasing from US$ 324.8 million in 2022, with the CAGR of 13.5% during the period of 2024 to 2029. Demand from Cell Carcinoma and Solid Tumor are the major drivers for the industry.
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a protein receptor found on various immune cells, including T cells and natural killer (NK) cells. It plays a role in regulating immune responses, and targeting TIGIT has emerged as a potential therapeutic strategy for cancer and autoimmune diseases.
Clinical trials were underway to evaluate the safety and efficacy of anti-TIGIT antibodies either as monotherapy or in combination with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies). Promising results were reported from early-stage trials, showing potential benefits in various solid tumors, including lung cancer, melanoma, and gastrointestinal cancers.
The market for anti-TIGIT antibodies was expected to grow as more clinical data became available.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-TIGIT Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Roche
Merck
AstraZeneca
Arcus
Astellas
BeiGene
BMS
Junshi Biosciences
Innovent Biologics
Mereo BioPharma
Seattle Genetics
Hengrui Medicine
Compugen
Gilead Sciences
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Cell Carcinoma
Solid Tumor
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Anti-TIGIT Antibody market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Anti-TIGIT Antibody introduction, etc. Anti-TIGIT Antibody Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Anti-TIGIT Antibody market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices